Editas Medicine Inc (EDIT)vsRevolution Medicines Inc (RVMD)
EDIT
Editas Medicine Inc
$2.70
+1.89%
HEALTHCARE · Cap: $469.95M
RVMD
Revolution Medicines Inc
$203.77
+0.21%
HEALTHCARE · Cap: $44.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Editas Medicine Inc generates 6235% more annual revenue ($47.01M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -157.3%. EDIT earns a higher WallStSmart Score of 31/100 (F).
EDIT
Avoid31
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 232.3% year-over-year
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -70.2% — below average capital efficiency
Trading at 16.8x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : EDIT
The strongest argument for EDIT centers on Revenue Growth, Debt/Equity. Revenue growth of 232.3% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : EDIT
The primary concerns for EDIT are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
EDIT profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.
EDIT carries more volatility with a beta of 2.06 — expect wider price swings.
EDIT is growing revenue faster at 232.3% — sustainability is the question.
EDIT generates stronger free cash flow (-30M), providing more financial flexibility.
Bottom Line
EDIT scores higher overall (31/100 vs 24/100) and 232.3% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Editas Medicine Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?